Torasemide - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (4)

Targets (1)Enzymes (4)Biointeractions (5)

Identification

Name

Torasemide

Accession Number

DB00214 (APRD00295, APRD00217)

Type

Small Molecule

Groups

Approved

Description

Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. [Wikipedia]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea

Demadex

Luprac

N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide

Torasemida

Torasemidum

Torsemide

External IDs

AC-4464 / AC4464 / BM02.015

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Demadex	Tablet	100 mg/1	Oral	Meda Pharmaceuticals Ltd	2009-02-20	2016-01-20	US
Demadex	Tablet	10 mg/1	Oral	Meda Pharmaceuticals Ltd	2015-01-01	Not applicable	US
Demadex	Tablet	20 mg/1	Oral	Meda Pharmaceuticals Ltd	2009-02-20	2016-01-20	US
Demadex	Tablet	5 mg/1	Oral	Meda Pharmaceuticals Ltd	2015-01-01	Not applicable	US
Demadex	Tablet	5 mg/1	Oral	Meda Pharmaceuticals Ltd	2009-02-20	2016-01-20	US
Demadex	Tablet	100 mg/1	Oral	Meda Pharmaceuticals Ltd	2015-01-01	Not applicable	US
Demadex	Tablet	10 mg/1	Oral	Physicians Total Care, Inc.	2000-11-28	Not applicable	US
Demadex	Tablet	20 mg/1	Oral	Meda Pharmaceuticals Ltd	2015-01-01	Not applicable	US
Demadex	Tablet	10 mg/1	Oral	Meda Pharmaceuticals Ltd	2009-02-20	2016-01-20	US
Demadex	Tablet	20 mg/1	Oral	Physicians Total Care, Inc.	2009-10-21	Not applicable	US
Demadex Injection - 10mg/ml	Liquid	10 mg	Intravenous	Hoffmann La Roche	1995-12-31	2000-07-27	Canada
Demadex Tablets - 100mg	Tablet	100 mg	Oral	Hoffmann La Roche	1995-12-31	2000-07-27	Canada
Demadex Tablets - 10mg	Tablet	10 mg	Oral	Hoffmann La Roche	1995-12-31	2000-07-27	Canada
Demadex Tablets - 20mg	Tablet	20 mg	Oral	Hoffmann La Roche	1996-12-31	2000-07-27	Canada
Demadex Tablets - 5mg	Tablet	5 mg	Oral	Hoffmann La Roche	1995-12-31	2000-07-27	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Torsemide	Tablet	20 mg/1	Oral	bryant ranch prepack	2009-01-27	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Sun Pharmaceutical Industries Limited	2008-02-26	2017-02-22	US
Torsemide	Tablet	10 mg/1	Oral	Camber Pharmaceuticals	2011-01-01	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Teva	2004-06-01	Not applicable	US
Torsemide	Injection, solution	10 mg/mL	Intravenous	General Injectables & Vaccines	2010-06-01	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Par Pharmaceutical	2009-01-27	2016-10-13	US
Torsemide	Tablet	5 mg/1	Oral	Av Kare, Inc.	2017-04-03	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Cardinal Health	2010-01-14	Not applicable	US
Torsemide	Injection, solution	10 mg/mL	Intravenous	American Regent	2010-05-21	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Aurobindo Pharma	2007-10-17	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Physicians Total Care, Inc.	2012-08-17	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Apotex Corporation	2005-06-06	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Av Pak	2014-10-07	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Citron Pharma LLC	2007-10-17	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Qualitest	2011-03-22	2016-11-08	US
Torsemide	Tablet	100 mg/1	Oral	Av Kare, Inc.	2014-12-29	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Cardinal Health	2010-01-14	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Carilion Materials Management	2011-01-01	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	bryant ranch prepack	2011-01-01	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Par Pharmaceutical	2009-01-27	2016-10-13	US
Torsemide	Tablet	100 mg/1	Oral	Teva	2004-10-20	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-01-01	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Aurobindo Pharma	2007-10-17	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Av Pak	2014-10-07	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Citron Pharma LLC	2007-10-17	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-07-19	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Avera Mc Kennan Hospital	2016-01-26	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Physicians Total Care, Inc.	2005-04-01	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Amerincan Health Packaging	2013-07-22	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Sun Pharmaceutical Industries Limited	2008-02-26	2017-02-22	US
Torsemide	Tablet	20 mg/1	Oral	Camber Pharmaceuticals	2011-01-01	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Teva	2004-06-01	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Apotex Corporation	2005-06-06	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Par Pharmaceutical	2009-01-27	2016-10-13	US
Torsemide	Tablet	10 mg/1	Oral	Av Kare, Inc.	2017-04-03	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Cardinal Health	2004-06-01	Not applicable	US
Torsemide	Injection, solution	10 mg/mL	Intravenous	American Regent	2010-05-26	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Apotex Corporation	2005-06-06	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Av Pak	2014-10-07	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Citron Pharma LLC	2007-10-17	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Qualitest	2011-03-22	2016-11-08	US
Torsemide	Tablet	20 mg/1	Oral	Carilion Materials Management	2011-01-01	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Avera Mc Kennan Hospital	2015-10-29	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Aurobindo Pharma	2007-10-17	Not applicable	US
Torsemide	Injection	10 mg/mL	Intravenous	General Injectables & Vaccines	2010-06-01	2017-01-28	US
Torsemide	Tablet	5 mg/1	Oral	Sun Pharmaceutical Industries Limited	2008-02-26	2017-02-22	US
Torsemide	Tablet	5 mg/1	Oral	Camber Pharmaceuticals	2011-01-01	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Av Kare, Inc.	2017-04-03	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Cardinal Health	2004-06-01	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Qualitest	2011-03-22	2016-11-08	US
Torsemide	Tablet	20 mg/1	Oral	Avera Mc Kennan Hospital	2016-01-11	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Physicians Total Care, Inc.	2009-06-26	Not applicable	US
Torsemide	Tablet	5 mg/1	Oral	Carilion Materials Management	2011-01-01	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Sun Pharmaceutical Industries Limited	2008-02-26	2017-02-22	US
Torsemide	Tablet	100 mg/1	Oral	Camber Pharmaceuticals	2011-01-01	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Teva	2004-06-01	Not applicable	US
Torsemide	Tablet	10 mg/1	Oral	Apotex Corporation	2005-06-06	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Par Pharmaceutical	2009-01-27	2016-10-13	US
Torsemide	Tablet	5 mg/1	Oral	Aurobindo Pharma	2007-10-17	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Av Pak	2014-10-07	Not applicable	US
Torsemide	Tablet	20 mg/1	Oral	Citron Pharma LLC	2007-10-17	Not applicable	US
Torsemide	Tablet	100 mg/1	Oral	Qualitest	2011-03-22	2016-11-08	US
Torsemide	Tablet	20 mg/1	Oral	West Ward Pharmaceutical	2005-03-03	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Diuver	Not Available
Examide	Not Available
Luprac	Not Available

Brand mixtures

Not Available

Categories

UNII

W31X2H97FB

CAS number

56211-40-6

Weight

Average: 348.42
Monoisotopic: 348.125611216

Chemical Formula

C₁₆H₂₀N₄O₃S

InChI Key

NGBFQHCMQULJNZ-UHFFFAOYSA-N

InChI

InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

IUPAC Name

1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea

SMILES

CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1

Pharmacology

Indication

For the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Structured Indications

Pharmacodynamics

Torasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorption is accomplished by a Na⁺/K⁺/2Cl^- symporter. The thick ascending limb has a high reabsorptive capacity and is responsible for reabsorbing 25% of the filtered load of Na⁺. The loop diuretics act by blocking this symporter. Because of the large absorptive capacity and the amount of Na⁺ delivered to the ascending limb, loop diuretics have a profound diuretic action. In addition, more distal nephron segments do not have the reabsorptive capacity to compensate for this increased load. The osmotic gradient for water reabsorption is also reduced resulting in an increase in the amount of water excreted.

Mechanism of action

Torasemide inhibits the Na⁺/K⁺/2Cl^--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and By increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Solute carrier family 12 member 1	Protein	yes	inhibitor	Human	Q13621	details

Absorption

Rapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption.

Volume of distribution

12 to 15 L [normal adults or in patients with mild to moderate renal failure or congestive heart failure]

Protein binding

> 99%

Metabolism

Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.

Substrate	Enzymes	Product
Torasemide	Cytochrome P450 2C8 Cytochrome P450 2C9	hydroxytorsemide	Details

Route of elimination

Torsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function).

Half life

3.5 hours

Clearance

Not Available

Toxicity

Symptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD₅₀ in rat is 5 g/kg, and intravenous LD₅₀ in rat is 500 mg/kg.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Torsemide Action Pathway	Drug action	SMP00118

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	16-Bromoepiandrosterone may increase the hypokalemic activities of Torasemide.	Investigational
19-norandrostenedione	19-norandrostenedione may increase the hypokalemic activities of Torasemide.	Experimental, Illicit
2,4-thiazolidinedione	The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Torasemide.	Investigational
5-androstenedione	5-androstenedione may increase the hypokalemic activities of Torasemide.	Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Torasemide.	Experimental
Abiraterone	The serum concentration of Torasemide can be increased when it is combined with Abiraterone.	Approved
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Torasemide.	Approved, Investigational
Acebutolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Acebutolol.	Approved
Aceclofenac	Aceclofenac may decrease the diuretic activities of Torasemide.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Torasemide is combined with Acetazolamide.	Approved, Vet Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide.	Withdrawn
Acetyldigitoxin	The risk or severity of adverse effects can be increased when Torasemide is combined with Acetyldigitoxin.	Approved
Acetylsalicylic acid	Acetylsalicylic acid may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Aclarubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Aclarubicin.	Investigational
Adapalene	Adapalene may decrease the diuretic activities of Torasemide.	Approved
AICA ribonucleotide	The therapeutic efficacy of Aicar can be decreased when used in combination with Torasemide.	Experimental
Alclometasone	Alclometasone may increase the hypokalemic activities of Torasemide.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.	Approved
Aldosterone	Aldosterone may increase the hypokalemic activities of Torasemide.	Experimental
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the hypotensive activities of Torasemide.	Approved, Investigational
Aliskiren	The risk or severity of adverse effects can be increased when Torasemide is combined with Aliskiren.	Approved, Investigational
Allopurinol	The risk or severity of adverse effects can be increased when Torasemide is combined with Allopurinol.	Approved
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Torasemide.	Experimental, Illicit
Alprenolol	Torasemide may increase the hypotensive activities of Alprenolol.	Approved, Withdrawn
Ambrisentan	Torasemide may increase the hypotensive activities of Ambrisentan.	Approved, Investigational
Amcinonide	Amcinonide may increase the hypokalemic activities of Torasemide.	Approved
Amifostine	Torasemide may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amikacin	The risk or severity of adverse effects can be increased when Torasemide is combined with Amikacin.	Approved, Vet Approved
Amiloride	The risk or severity of adverse effects can be increased when Torasemide is combined with Amiloride.	Approved
Aminosalicylic Acid	Aminosalicylic Acid may decrease the diuretic activities of Torasemide.	Approved
Amiodarone	The metabolism of Torasemide can be decreased when combined with Amiodarone.	Approved, Investigational
Amlodipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Amlodipine.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Torasemide.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Torasemide is combined with Amphotericin B.	Approved, Investigational
Amrubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Amrubicin.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Torasemide is combined with Amyl Nitrite.	Approved
Andrographolide	HMPL-004 may decrease the diuretic activities of Torasemide.	Investigational
Androstenedione	4-Androstenedione may increase the hypokalemic activities of Torasemide.	Experimental, Illicit
Anecortave	Anecortave may increase the hypokalemic activities of Torasemide.	Investigational
Anisodamine	Anisodamine may decrease the diuretic activities of Torasemide.	Investigational
Antipyrine	Antipyrine may decrease the diuretic activities of Torasemide.	Approved
Apocynin	Acetovanillone may decrease the diuretic activities of Torasemide.	Investigational
Apomorphine	The risk or severity of adverse effects can be increased when Torasemide is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Torasemide is combined with Apraclonidine.	Approved
Apramycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Apramycin.	Experimental, Vet Approved
Apremilast	Apremilast may decrease the diuretic activities of Torasemide.	Approved, Investigational
Aprepitant	The metabolism of Torasemide can be increased when combined with Aprepitant.	Approved, Investigational
Arbekacin	The risk or severity of adverse effects can be increased when Torasemide is combined with Arbekacin.	Approved
Arbutamine	Arbutamine may increase the hypokalemic activities of Torasemide.	Approved
Arformoterol	Arformoterol may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Torasemide.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Arotinolol.	Approved
Arsenic trioxide	The risk or severity of adverse effects can be increased when Torasemide is combined with Arsenic trioxide.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Atenolol.	Approved
Atracurium besylate	Torasemide may decrease the neuromuscular blocking activities of Atracurium besylate.	Approved
Azapropazone	Azapropazone may decrease the diuretic activities of Torasemide.	Withdrawn
Azelastine	Azelastine may decrease the diuretic activities of Torasemide.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Torasemide is combined with Azilsartan medoxomil.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Torasemide.	Investigational
Balsalazide	Balsalazide may decrease the diuretic activities of Torasemide.	Approved, Investigational
Bambuterol	Bambuterol may increase the hypokalemic activities of Torasemide.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Torasemide.	Experimental
Barbital	Barbital may increase the hypotensive activities of Torasemide.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Barnidipine.	Approved
Beclomethasone dipropionate	Beclomethasone dipropionate may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Benazepril	The risk or severity of adverse effects can be increased when Torasemide is combined with Benazepril.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Torasemide is combined with Bendroflumethiazide.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Torasemide.	Withdrawn
Benoxaprofen	Benoxaprofen may decrease the diuretic activities of Torasemide.	Withdrawn
Bepridil	Torasemide may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Betamethasone	Betamethasone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Torasemide.	Approved
Bethanidine	Torasemide may increase the hypotensive activities of Bethanidine.	Approved
Betulinic Acid	Betulinic Acid may decrease the diuretic activities of Torasemide.	Investigational
Bezitramide	The risk or severity of adverse effects can be increased when Bezitramide is combined with Torasemide.	Experimental, Illicit, Withdrawn
Bimatoprost	Torasemide may increase the hypotensive activities of Bimatoprost.	Approved, Investigational
Bisoprolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Bisoprolol.	Approved
Bortezomib	The risk or severity of adverse effects can be increased when Torasemide is combined with Bortezomib.	Approved, Investigational
Bosentan	Torasemide may increase the hypotensive activities of Bosentan.	Approved, Investigational
Bretylium	The risk or severity of adverse effects can be increased when Torasemide is combined with Bretylium.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Torasemide is combined with Brimonidine.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Torasemide.	Approved
Bromfenac	Bromfenac may decrease the diuretic activities of Torasemide.	Approved
Bromocriptine	The risk or severity of adverse effects can be increased when Torasemide is combined with Bromocriptine.	Approved, Investigational
Bucillamine	Bucillamine may decrease the diuretic activities of Torasemide.	Investigational
Budesonide	Budesonide may increase the hypokalemic activities of Torasemide.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Torasemide.	Withdrawn
Bumetanide	The risk or severity of adverse effects can be increased when Torasemide is combined with Bumetanide.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Torasemide is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Torasemide may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.	Approved, Illicit, Investigational, Vet Approved
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.	Approved, Illicit, Vet Approved
Canagliflozin	Canagliflozin may increase the hypotensive activities of Torasemide.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Candesartan.	Approved
Candoxatril	Torasemide may increase the hypotensive activities of Candoxatril.	Experimental
Capecitabine	The metabolism of Torasemide can be decreased when combined with Capecitabine.	Approved, Investigational
Captopril	The risk or severity of adverse effects can be increased when Torasemide is combined with Captopril.	Approved
Carbamazepine	The metabolism of Torasemide can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Torasemide is combined with Carbetocin.	Approved
Carfentanil	The risk or severity of adverse effects can be increased when Carfentanil is combined with Torasemide.	Illicit, Vet Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Torasemide.	Withdrawn
Carprofen	Carprofen may decrease the diuretic activities of Torasemide.	Approved, Vet Approved, Withdrawn
Carteolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Carteolol.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Torasemide is combined with Carvedilol.	Approved, Investigational
Castanospermine	Castanospermine may decrease the diuretic activities of Torasemide.	Experimental
Celecoxib	Celecoxib may decrease the diuretic activities of Torasemide.	Approved, Investigational
Celiprolol	Celiprolol may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Ceritinib	The serum concentration of Torasemide can be increased when it is combined with Ceritinib.	Approved
Chloroquine	Chloroquine may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Torasemide is combined with Chlorothiazide.	Approved, Vet Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Torasemide is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.	Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Torasemide is combined with Chlorthalidone.	Approved
Cholecalciferol	The metabolism of Torasemide can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Choline magnesium trisalicylate	Trisalicylate-choline may decrease the diuretic activities of Torasemide.	Approved
Ciclesonide	Ciclesonide may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Torasemide.	Experimental
Cilazapril	The risk or severity of adverse effects can be increased when Torasemide is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Cilnidipine.	Approved
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Torasemide.	Approved
Cisatracurium besylate	Torasemide may decrease the neuromuscular blocking activities of Cisatracurium besylate.	Approved
Cisplatin	Torasemide may increase the nephrotoxic activities of Cisplatin.	Approved
Clenbuterol	Clenbuterol may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Clevidipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.	Approved
Clobetasol	Clobetasol may increase the hypokalemic activities of Torasemide.	Investigational
Clobetasol propionate	Clobetasol propionate may increase the hypokalemic activities of Torasemide.	Approved
Clocortolone	Clocortolone may increase the hypokalemic activities of Torasemide.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Torasemide is combined with Clofarabine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Torasemide is combined with Clomipramine.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Torasemide is combined with Clonidine.	Approved
Clonixin	Clonixin may decrease the diuretic activities of Torasemide.	Approved
Clopidogrel	The metabolism of Torasemide can be decreased when combined with Clopidogrel.	Approved, Nutraceutical
Clotrimazole	The metabolism of Torasemide can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Torasemide is combined with Clozapine.	Approved
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Torasemide.	Approved, Illicit
Colesevelam	Colesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Torasemide is combined with Conivaptan.	Approved, Investigational
Cortisone acetate	Cortisone acetate may increase the hypokalemic activities of Torasemide.	Approved
Cryptenamine	Torasemide may increase the hypotensive activities of Cryptenamine.	Approved
Curcumin	Curcumin may decrease the diuretic activities of Torasemide.	Investigational
Cyclosporine	The risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.	Approved, Investigational, Vet Approved
Cyclosporine	The metabolism of Torasemide can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	Torasemide may increase the hypotensive activities of Cyclothiazide.	Approved
Dabrafenib	The serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin.	Approved
Daunorubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Daunorubicin.	Approved
Debrisoquin	Torasemide may increase the hypotensive activities of Debrisoquin.	Approved
Decamethonium	Torasemide may decrease the neuromuscular blocking activities of Decamethonium.	Approved
Deferasirox	The serum concentration of Torasemide can be increased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Torasemide can be decreased when combined with Delavirdine.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Torasemide.	Investigational
Deserpidine	Torasemide may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Torasemide is combined with Desflurane.	Approved
Deslanoside	The risk or severity of adverse effects can be increased when Torasemide is combined with Deslanoside.	Approved
Desoximetasone	Desoximetasone may increase the hypokalemic activities of Torasemide.	Approved
Desoxycorticosterone Pivalate	Desoxycorticosterone Pivalate may increase the hypokalemic activities of Torasemide.	Experimental, Vet Approved
Dexamethasone	Dexamethasone may increase the hypokalemic activities of Torasemide.	Approved, Investigational, Vet Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Torasemide is combined with Dexmedetomidine.	Approved, Vet Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Dextromoramide is combined with Torasemide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Torasemide.	Approved, Illicit, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Dezocine is combined with Torasemide.	Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Torasemide.	Approved
Diclofenac	Diclofenac may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Torasemide is combined with Diclofenamide.	Approved
Diflorasone	Diflorasone may increase the hypokalemic activities of Torasemide.	Approved
Diflunisal	Diflunisal may decrease the diuretic activities of Torasemide.	Approved
Difluocortolone	Difluocortolone may increase the hypokalemic activities of Torasemide.	Approved
Difluprednate	Difluprednate may increase the hypokalemic activities of Torasemide.	Approved
Digitoxin	The risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.	Approved
Digoxin	The risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.	Approved
Dihydralazine	Torasemide may increase the hypotensive activities of Dihydralazine.	Investigational
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.	Approved, Illicit
Dihydroetorphine	The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Torasemide.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Torasemide.	Experimental, Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Torasemide is combined with Diltiazem.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Torasemide is combined with Dinutuximab.	Approved
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide.	Approved, Illicit
Dipivefrin	Dipivefrin may increase the hypokalemic activities of Torasemide.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Torasemide is combined with Dipyridamole.	Approved
Dobutamine	Dobutamine may increase the hypokalemic activities of Torasemide.	Approved
Dofetilide	Torasemide may increase the QTc-prolonging activities of Dofetilide.	Approved
Domoic Acid	Torasemide may decrease the neuromuscular blocking activities of Domoic Acid.	Experimental
Dorzolamide	Torasemide may increase the hypotensive activities of Dorzolamide.	Approved
Doxacurium chloride	Torasemide may decrease the neuromuscular blocking activities of Doxacurium chloride.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Torasemide is combined with Doxazosin.	Approved
Doxorubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Doxorubicin.	Approved, Investigational
Droxicam	Droxicam may decrease the diuretic activities of Torasemide.	Approved
Droxidopa	Droxidopa may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Torasemide.	Approved
Duloxetine	Torasemide may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Duvelisib	Duvelisib may decrease the diuretic activities of Torasemide.	Investigational
E-6201	E6201 may decrease the diuretic activities of Torasemide.	Investigational
Ebselen	Ebselen may decrease the diuretic activities of Torasemide.	Investigational
Efavirenz	The metabolism of Torasemide can be decreased when combined with Efavirenz.	Approved, Investigational
Efonidipine	Torasemide may increase the hypotensive activities of Efonidipine.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Torasemide is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Torasemide is combined with Enalapril.	Approved, Vet Approved
Enalaprilat	Torasemide may increase the hypotensive activities of Enalaprilat.	Approved
Ephedra	Ephedra may increase the hypokalemic activities of Torasemide.	Approved, Nutraceutical, Withdrawn
Epinephrine	Epinephrine may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Epirizole	Epirizole may decrease the diuretic activities of Torasemide.	Approved
Epirubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Epirubicin.	Approved
Eplerenone	The risk or severity of adverse effects can be increased when Torasemide is combined with Eplerenone.	Approved
Epoprostenol	Torasemide may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Eprosartan.	Approved
Equilenin	Equilenin may increase the hypokalemic activities of Torasemide.	Experimental
Equilin	Equilin may increase the hypokalemic activities of Torasemide.	Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Torasemide.	Approved
Estrone	Estrone may increase the hypokalemic activities of Torasemide.	Approved
Estrone sulfate	Estrone sulfate may increase the hypokalemic activities of Torasemide.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.	Approved
Etanercept	Etanercept may decrease the diuretic activities of Torasemide.	Approved, Investigational
Ethylmorphine	The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Torasemide.	Approved, Illicit
Etodolac	Etodolac may decrease the diuretic activities of Torasemide.	Approved, Investigational, Vet Approved
Etofenamate	Etofenamate may decrease the diuretic activities of Torasemide.	Approved
Etoricoxib	Etoricoxib may decrease the diuretic activities of Torasemide.	Approved, Investigational
Etorphine	The risk or severity of adverse effects can be increased when Etorphine is combined with Torasemide.	Illicit, Vet Approved
Etravirine	The metabolism of Torasemide can be decreased when combined with Etravirine.	Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Torasemide.	Approved, Investigational
Felodipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Felodipine.	Approved, Investigational
Fenbufen	Fenbufen may decrease the diuretic activities of Torasemide.	Approved
Fenoldopam	Torasemide may increase the hypotensive activities of Fenoldopam.	Approved
Fenoprofen	Fenoprofen may decrease the diuretic activities of Torasemide.	Approved
Fenoterol	Fenoterol may increase the hypokalemic activities of Torasemide.	Approved
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.	Approved, Illicit, Investigational, Vet Approved
Fimasartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Fimasartan.	Approved
Floctafenine	Floctafenine may decrease the diuretic activities of Torasemide.	Approved, Withdrawn
Floxuridine	The metabolism of Torasemide can be decreased when combined with Floxuridine.	Approved
Fluconazole	The metabolism of Torasemide can be decreased when combined with Fluconazole.	Approved
Fludrocortisone	Fludrocortisone may increase the hypokalemic activities of Torasemide.	Approved
Flumethasone	Flumethasone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Flunisolide	Flunisolide may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Fluocinolone Acetonide	Fluocinolone Acetonide may increase the hypokalemic activities of Torasemide.	Approved, Investigational, Vet Approved
Fluocinonide	Fluocinonide may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Fluocortolone	Fluocortolone may increase the hypokalemic activities of Torasemide.	Approved, Withdrawn
Fluorometholone	Fluorometholone may increase the hypokalemic activities of Torasemide.	Approved
Fluorouracil	The metabolism of Torasemide can be decreased when combined with Fluorouracil.	Approved
Fluprednidene	Fluprednidene may increase the hypokalemic activities of Torasemide.	Approved, Withdrawn
Flurandrenolide	Flurandrenolide may increase the hypokalemic activities of Torasemide.	Approved
Flurbiprofen	Flurbiprofen may decrease the diuretic activities of Torasemide.	Approved, Investigational
Fluticasone furoate	Fluticasone furoate may increase the hypokalemic activities of Torasemide.	Approved
Fluticasone propionate	Fluticasone Propionate may increase the hypokalemic activities of Torasemide.	Approved
Fluvastatin	The metabolism of Torasemide can be decreased when combined with Fluvastatin.	Approved
Fluvoxamine	The metabolism of Torasemide can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formestane	Formestane may increase the hypokalemic activities of Torasemide.	Approved, Investigational, Withdrawn
Formoterol	Formoterol may increase the hypokalemic activities of Torasemide.	Approved, Investigational
Foscarnet	The serum concentration of Foscarnet can be increased when it is combined with Torasemide.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Torasemide is combined with Fosinopril.	Approved
Fosphenytoin	Fosphenytoin may decrease the diuretic activities of Torasemide.	Approved
Framycetin	The risk or severity of adverse effects can be increased when Torasemide is combined with Framycetin.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Torasemide.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Furosemide.	Approved, Vet Approved
Gallamine Triethiodide	Torasemide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.	Approved
Gemfibrozil	The metabolism of Torasemide can be decreased when combined with Gemfibrozil.	Approved
Geneticin	The risk or severity of adverse effects can be increased when Torasemide is combined with Geneticin.	Experimental
Gentamicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Gentamicin.	Approved, Vet Approved
GENTAMICIN C1A	The risk or severity of adverse effects can be increased when Torasemide is combined with GENTAMICIN C1A.	Experimental
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Torasemide.	Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Torasemide.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Torasemide.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.	Approved
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Torasemide.	Approved
Guanabenz	Torasemide may increase the hypotensive activities of Guanabenz.	Approved
Guanadrel	Torasemide may increase the hypotensive activities of Guanadrel.	Approved
Guanethidine	Torasemide may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Torasemide is combined with Guanfacine.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Torasemide.	Investigational
Halothane	The risk or severity of adverse effects can be increased when Torasemide is combined with Halothane.	Approved, Vet Approved
HE3286	HE3286 may increase the hypokalemic activities of Torasemide.	Investigational
Heroin	The risk or severity of adverse effects can be increased when Heroin is combined with Torasemide.	Approved, Illicit
Hexamethonium	Torasemide may increase the hypotensive activities of Hexamethonium.	Experimental
Hexobarbital	Hexobarbital may increase the hypotensive activities of Torasemide.	Approved
Higenamine	Higenamine may decrease the diuretic activities of Torasemide.	Investigational
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Torasemide.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Torasemide is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Torasemide is combined with Hydrochlorothiazide.	Approved, Vet Approved
Hydrocodone	The risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.	Approved, Illicit
Hydrocortisone	Hydrocortisone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Hydroflumethiazide	Torasemide may increase the hypotensive activities of Hydroflumethiazide.	Approved
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.	Approved, Illicit
Ibuprofen	Ibuprofen may decrease the diuretic activities of Torasemide.	Approved
Ibuproxam	Ibuproxam may decrease the diuretic activities of Torasemide.	Withdrawn
Icatibant	Icatibant may decrease the diuretic activities of Torasemide.	Approved
Idarubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Idarubicin.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Torasemide.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Torasemide is combined with Imidapril.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Torasemide is combined with Imipramine.	Approved
Indacaterol	Indacaterol may increase the hypokalemic activities of Torasemide.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Torasemide is combined with Indapamide.	Approved
Indenolol	Torasemide may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Torasemide can be decreased when combined with Indinavir.	Approved
Indomethacin	Indomethacin may decrease the diuretic activities of Torasemide.	Approved, Investigational
Indoprofen	Indoprofen may decrease the diuretic activities of Torasemide.	Withdrawn
Indoramin	Torasemide may increase the hypotensive activities of Indoramin.	Withdrawn
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Torasemide.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Torasemide.	Approved
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Torasemide.	Approved
Iproclozide	Iproclozide may increase the hypotensive activities of Torasemide.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Torasemide.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Irbesartan.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Torasemide.	Approved
Isoetarine	Isoetarine may increase the hypokalemic activities of Torasemide.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Torasemide is combined with Isoflurane.	Approved, Vet Approved
Isoprenaline	Isoprenaline may increase the hypokalemic activities of Torasemide.	Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Dinitrate.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate.	Approved
Isoxicam	Isoxicam may decrease the diuretic activities of Torasemide.	Withdrawn
Isoxsuprine	The risk or severity of adverse effects can be increased when Torasemide is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Isradipine.	Approved
Ivabradine	Torasemide may increase the arrhythmogenic activities of Ivabradine.	Approved
Kanamycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Kanamycin.	Approved, Vet Approved
Kebuzone	Kebuzone may decrease the diuretic activities of Torasemide.	Experimental
Ketanserin	Torasemide may increase the hypotensive activities of Ketanserin.	Investigational
Ketobemidone	The risk or severity of adverse effects can be increased when Ketobemidone is combined with Torasemide.	Approved
Ketoconazole	The metabolism of Torasemide can be decreased when combined with Ketoconazole.	Approved, Investigational
Ketoprofen	Ketoprofen may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Ketorolac	Ketorolac may decrease the diuretic activities of Torasemide.	Approved
Labetalol	The risk or severity of adverse effects can be increased when Torasemide is combined with Labetalol.	Approved
Lacidipine	Torasemide may increase the hypotensive activities of Lacidipine.	Approved
Lapatinib	The metabolism of Torasemide can be decreased when combined with Lapatinib.	Approved, Investigational
Latanoprost	Torasemide may increase the hypotensive activities of Latanoprost.	Approved, Investigational
Leflunomide	Leflunomide may decrease the diuretic activities of Torasemide.	Approved, Investigational
Lercanidipine	Torasemide may increase the hypotensive activities of Lercanidipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Torasemide is combined with Levobupivacaine.	Approved
Levodopa	Torasemide may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Torasemide.	Approved
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Torasemide is combined with Levosimendan.	Approved, Investigational
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Torasemide.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Torasemide is combined with Lisinopril.	Approved, Investigational
Lisofylline	Lisofylline may decrease the diuretic activities of Torasemide.	Investigational
Lithium	The serum concentration of Lithium can be decreased when it is combined with Torasemide.	Approved
Lofentanil	The risk or severity of adverse effects can be increased when Lofentanil is combined with Torasemide.	Illicit
Lofexidine	Torasemide may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Lopinavir	The metabolism of Torasemide can be decreased when combined with Lopinavir.	Approved
Lornoxicam	Lornoxicam may decrease the diuretic activities of Torasemide.	Approved
Losartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Losartan.	Approved
Lovastatin	The metabolism of Torasemide can be decreased when combined with Lovastatin.	Approved, Investigational
Loxoprofen	Loxoprofen may decrease the diuretic activities of Torasemide.	Approved
Lumacaftor	The serum concentration of Torasemide can be increased when it is combined with Lumacaftor.	Approved
Lumiracoxib	Lumiracoxib may decrease the diuretic activities of Torasemide.	Approved, Investigational
Macitentan	Torasemide may increase the hypotensive activities of Macitentan.	Approved
Magnesium salicylate	Magnesium salicylate may decrease the diuretic activities of Torasemide.	Approved
Manidipine	Torasemide may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Torasemide is combined with Mannitol.	Approved, Investigational
Masoprocol	Masoprocol may decrease the diuretic activities of Torasemide.	Approved
ME-609	ME-609 may increase the hypokalemic activities of Torasemide.	Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Torasemide.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Torasemide is combined with Mecamylamine.	Approved
Meclofenamic acid	Meclofenamic acid may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Medrysone	Medrysone may increase the hypokalemic activities of Torasemide.	Approved
Mefenamic acid	Mefenamic acid may decrease the diuretic activities of Torasemide.	Approved
Meloxicam	Meloxicam may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Mesalazine	Mesalazine may decrease the diuretic activities of Torasemide.	Approved
Metamizole	Metamizole may decrease the diuretic activities of Torasemide.	Withdrawn
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Torasemide.	Approved, Illicit
Methazolamide	The risk or severity of adverse effects can be increased when Torasemide is combined with Methazolamide.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Torasemide.	Approved
Methotrexate	The therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Torasemide is combined with Methyclothiazide.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Torasemide is combined with Methyldopa.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Torasemide.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Torasemide.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Torasemide.	Approved
Methylprednisolone	Methylprednisolone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Metipranolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Metipranolol.	Approved
Metocurine	Torasemide may decrease the neuromuscular blocking activities of Metocurine.	Approved
Metocurine Iodide	Torasemide may decrease the neuromuscular blocking activities of Metocurine Iodide.	Withdrawn
Metolazone	The risk or severity of adverse effects can be increased when Torasemide is combined with Metolazone.	Approved
Metoprolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Metoprolol.	Approved, Investigational
Metrizamide	The risk or severity of adverse effects can be increased when Torasemide is combined with Metrizamide.	Approved
Metyrosine	Torasemide may increase the hypotensive activities of Metyrosine.	Approved
Mibefradil	Torasemide may increase the hypotensive activities of Mibefradil.	Withdrawn
Mifepristone	The serum concentration of Torasemide can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Torasemide.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Torasemide.	Approved
Minaprine	Minaprine may increase the hypotensive activities of Torasemide.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Torasemide is combined with Minoxidil.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Torasemide.	Approved, Investigational
Mivacurium	Torasemide may decrease the neuromuscular blocking activities of Mivacurium.	Approved
Mizoribine	Mizoribine may decrease the diuretic activities of Torasemide.	Investigational
Moclobemide	Moclobemide may increase the hypotensive activities of Torasemide.	Approved
Moexipril	The risk or severity of adverse effects can be increased when Torasemide is combined with Moexipril.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Torasemide.	Approved
Mometasone	Mometasone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.	Approved, Investigational
Moxonidine	Torasemide may increase the hypotensive activities of Moxonidine.	Approved
Mycophenolate mofetil	Mycophenolate mofetil may decrease the diuretic activities of Torasemide.	Approved, Investigational
Mycophenolic acid	Mycophenolic acid may decrease the diuretic activities of Torasemide.	Approved
Nabilone	The risk or severity of adverse effects can be increased when Torasemide is combined with Nabilone.	Approved, Investigational
Nabumetone	Nabumetone may decrease the diuretic activities of Torasemide.	Approved
Nadolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Nadolol.	Approved
Nafamostat	Nafamostat may decrease the diuretic activities of Torasemide.	Approved, Investigational
Naftifine	Naftifine may decrease the diuretic activities of Torasemide.	Approved
Naftopidil	Torasemide may increase the hypotensive activities of Naftopidil.	Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.	Approved
Naproxen	Naproxen may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Torasemide.	Approved, Investigational
NCX 1022	NCX 1022 may increase the hypokalemic activities of Torasemide.	Investigational
NCX 4016	NCX 4016 may decrease the diuretic activities of Torasemide.	Investigational
Neamine	The risk or severity of adverse effects can be increased when Torasemide is combined with Neamine.	Experimental
Nebivolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Nebivolol.	Approved, Investigational
Neomycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Neomycin.	Approved, Vet Approved
Neosaxitoxin	Torasemide may decrease the neuromuscular blocking activities of Neosaxitoxin.	Investigational
Nepafenac	Nepafenac may decrease the diuretic activities of Torasemide.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Torasemide is combined with Nesiritide.	Approved, Investigational
Netilmicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Netilmicin.	Approved
Nialamide	Nialamide may increase the hypotensive activities of Torasemide.	Withdrawn
Nicardipine	The metabolism of Torasemide can be decreased when combined with Nicardipine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Torasemide.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Nifedipine.	Approved
Niflumic Acid	Niflumic Acid may decrease the diuretic activities of Torasemide.	Approved
Niguldipine	Torasemide may increase the hypotensive activities of Niguldipine.	Experimental
Nilotinib	The metabolism of Torasemide can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	Torasemide may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	Nimesulide may decrease the diuretic activities of Torasemide.	Approved, Withdrawn
Nimodipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Nimodipine.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Torasemide is combined with Nisoldipine.	Approved
Nitrendipine	Torasemide may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Torasemide is combined with Nitric Oxide.	Approved
Nitroaspirin	Nitroaspirin may decrease the diuretic activities of Torasemide.	Investigational
Nitroglycerin	The risk or severity of adverse effects can be increased when Torasemide is combined with Nitroglycerin.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Torasemide is combined with Nitroprusside.	Approved
Norepinephrine	Norepinephrine may increase the hypokalemic activities of Torasemide.	Approved
Normethadone	The risk or severity of adverse effects can be increased when Normethadone is combined with Torasemide.	Approved, Illicit
Obinutuzumab	Torasemide may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Torasemide.	Withdrawn
Oleandrin	The risk or severity of adverse effects can be increased when Torasemide is combined with Anvirzel.	Experimental
Oleoyl-estrone	Oleoyl estrone may increase the hypokalemic activities of Torasemide.	Investigational
Olmesartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Olmesartan.	Approved, Investigational
Olodaterol	Olodaterol may increase the hypokalemic activities of Torasemide.	Approved
Olopatadine	Olopatadine may decrease the diuretic activities of Torasemide.	Approved
Olsalazine	Olsalazine may decrease the diuretic activities of Torasemide.	Approved
Omapatrilat	Torasemide may increase the hypotensive activities of Omapatrilat.	Investigational
Omeprazole	The metabolism of Torasemide can be decreased when combined with Omeprazole.	Approved, Investigational, Vet Approved
Opium	The risk or severity of adverse effects can be increased when Opium is combined with Torasemide.	Approved, Illicit
Orciprenaline	Orciprenaline may increase the hypokalemic activities of Torasemide.	Approved
Ouabain	The risk or severity of adverse effects can be increased when Torasemide is combined with Ouabain.	Approved
Oxaprozin	Oxaprozin may decrease the diuretic activities of Torasemide.	Approved
Oxprenolol	Torasemide may increase the hypotensive activities of Oxprenolol.	Approved
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide.	Approved, Investigational, Vet Approved
Oxyphenbutazone	Oxyphenbutazone may decrease the diuretic activities of Torasemide.	Withdrawn
Paclitaxel	The risk or severity of adverse effects can be increased when Torasemide is combined with Paclitaxel.	Approved, Vet Approved
Pancuronium	Torasemide may decrease the neuromuscular blocking activities of Pancuronium.	Approved
Papaverine	The risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.	Approved
Paramethasone	Paramethasone may increase the hypokalemic activities of Torasemide.	Approved
Parecoxib	Parecoxib may decrease the diuretic activities of Torasemide.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Torasemide.	Approved
Paromomycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Paromomycin.	Approved, Investigational
Penbutolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Penbutolol.	Approved, Investigational
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.	Approved, Vet Approved
Pentobarbital	Pentobarbital may increase the hypotensive activities of Torasemide.	Approved, Vet Approved
Pentolinium	Torasemide may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Torasemide.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Torasemide is combined with Perindopril.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Torasemide.	Approved
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Torasemide.	Approved, Withdrawn
Pheniprazine	Pheniprazine may increase the hypotensive activities of Torasemide.	Withdrawn
Phenobarbital	The metabolism of Torasemide can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	Torasemide may increase the hypotensive activities of Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Torasemide.	Withdrawn
Phentolamine	Torasemide may increase the hypotensive activities of Phentolamine.	Approved
Phenylbutazone	Phenylbutazone may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Phenylpropanolamine	Phenylpropanolamine may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved, Withdrawn
Phenytoin	Phenytoin may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Pimecrolimus	Pimecrolimus may decrease the diuretic activities of Torasemide.	Approved, Investigational
Pindolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Pindolol.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Torasemide.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Torasemide is combined with Pipamperone.	Approved
Pipecuronium	Torasemide may decrease the neuromuscular blocking activities of Pipecuronium.	Approved
Pirarubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Pirarubicin.	Investigational
Pirbuterol	Pirbuterol may increase the hypokalemic activities of Torasemide.	Approved
Pirfenidone	Pirfenidone may decrease the diuretic activities of Torasemide.	Investigational
Piritramide	The risk or severity of adverse effects can be increased when Piritramide is combined with Torasemide.	Investigational
Pirlindole	Pirlindole may increase the hypotensive activities of Torasemide.	Approved
Piroxicam	Piroxicam may decrease the diuretic activities of Torasemide.	Approved, Investigational
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Torasemide.	Withdrawn
Plicamycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Plicamycin.	Approved, Withdrawn
Polythiazide	Torasemide may increase the hypotensive activities of Polythiazide.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Torasemide is combined with Pramipexole.	Approved, Investigational
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Torasemide.	Approved, Investigational
Prasterone	Prasterone may increase the hypokalemic activities of Torasemide.	Approved, Nutraceutical
Prasterone sulfate	dehydroepiandrosterone sulfate may increase the hypokalemic activities of Torasemide.	Investigational
Prazosin	The risk or severity of adverse effects can be increased when Torasemide is combined with Prazosin.	Approved
Prednicarbate	Prednicarbate may increase the hypokalemic activities of Torasemide.	Approved
Prednisolone	Prednisolone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Prednisone	Prednisone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Pregnenolone	Pregnenolone may increase the hypokalemic activities of Torasemide.	Experimental
Primidone	The metabolism of Torasemide can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide.	Approved
Procaterol	Procaterol may increase the hypokalemic activities of Torasemide.	Approved
Propacetamol	Propacetamol may decrease the diuretic activities of Torasemide.	Approved
Propofol	The risk or severity of adverse effects can be increased when Torasemide is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Propranolol.	Approved, Investigational
PTC299	PTC299 may decrease the diuretic activities of Torasemide.	Investigational
Puromycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Puromycin.	Experimental
Pyrimethamine	The metabolism of Torasemide can be decreased when combined with Pyrimethamine.	Approved, Vet Approved
Quetiapine	The risk or severity of adverse effects can be increased when Torasemide is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Torasemide is combined with Quinapril.	Approved, Investigational
Quinine	Quinine may increase the hypotensive activities of Torasemide.	Approved
Rabeprazole	The metabolism of Torasemide can be decreased when combined with Rabeprazole.	Approved, Investigational
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide.	Approved
Rapacuronium	Torasemide may decrease the neuromuscular blocking activities of Rapacuronium.	Withdrawn
Rasagiline	Rasagiline may increase the hypotensive activities of Torasemide.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Torasemide.	Approved
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide.	Approved, Investigational
Rescinnamine	Torasemide may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Torasemide.	Approved
Resveratrol	Resveratrol may decrease the diuretic activities of Torasemide.	Experimental, Investigational
Ribostamycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.	Approved
Rifampicin	The metabolism of Torasemide can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Torasemide can be increased when combined with Rifapentine.	Approved
Rilmenidine	Torasemide may increase the hypotensive activities of Rilmenidine.	Investigational
Rimexolone	Rimexolone may increase the hypokalemic activities of Torasemide.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Torasemide is combined with Riociguat.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.	Approved, Investigational
Ritodrine	Ritodrine may increase the hypokalemic activities of Torasemide.	Approved
Ritonavir	The metabolism of Torasemide can be decreased when combined with Ritonavir.	Approved, Investigational
Rituximab	Torasemide may increase the hypotensive activities of Rituximab.	Approved
Rocuronium	Torasemide may decrease the neuromuscular blocking activities of Rocuronium.	Approved
Rofecoxib	Rofecoxib may decrease the diuretic activities of Torasemide.	Investigational, Withdrawn
Ropinirole	The risk or severity of adverse effects can be increased when Torasemide is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Torasemide is combined with Ropivacaine.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Torasemide.	Approved, Investigational
Rotigotine	The risk or severity of adverse effects can be increased when Torasemide is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Torasemide is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Torasemide.	Withdrawn
Salbutamol	Salbutamol may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Salicylamide	Salicylamide may decrease the diuretic activities of Torasemide.	Approved
Salicylic acid	Salicylic acid may decrease the diuretic activities of Torasemide.	Approved, Vet Approved
Salmeterol	Salmeterol may increase the hypokalemic activities of Torasemide.	Approved
Salsalate	Salsalate may decrease the diuretic activities of Torasemide.	Approved
Saprisartan	Torasemide may increase the hypotensive activities of Saprisartan.	Experimental
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Torasemide.	Approved
Secobarbital	The metabolism of Torasemide can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Torasemide.	Approved, Investigational, Vet Approved
Selexipag	Torasemide may increase the hypotensive activities of Selexipag.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Torasemide is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Torasemide.	Approved, Investigational
Sisomicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Sisomicin.	Investigational
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Torasemide.	Approved, Investigational
Sitaxentan	Torasemide may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium Nitrite	The risk or severity of adverse effects can be increased when Torasemide is combined with Sodium Nitrite.	Approved
Sorafenib	The metabolism of Torasemide can be decreased when combined with Sorafenib.	Approved, Investigational
Sotalol	The risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.	Approved
SP1049C	The risk or severity of adverse effects can be increased when Torasemide is combined with SP1049C.	Investigational
Spectinomycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Spectinomycin.	Approved, Vet Approved
Spirapril	Torasemide may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone.	Approved
SRT501	SRT501 may decrease the diuretic activities of Torasemide.	Investigational
Stiripentol	The metabolism of Torasemide can be decreased when combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Torasemide is combined with Streptokinase.	Approved
Streptomycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Streptomycin.	Approved, Vet Approved
Streptozocin	The risk or severity of adverse effects can be increased when Torasemide is combined with Streptozocin.	Approved
Succinylcholine	Torasemide may decrease the neuromuscular blocking activities of Succinylcholine.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.	Approved, Investigational
Sulfadiazine	The metabolism of Torasemide can be decreased when combined with Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Torasemide can be decreased when combined with Sulfamethoxazole.	Approved
Sulfasalazine	Sulfasalazine may decrease the diuretic activities of Torasemide.	Approved
Sulfisoxazole	The metabolism of Torasemide can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulindac	Sulindac may decrease the diuretic activities of Torasemide.	Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Torasemide.	Approved, Investigational
Sulpiride	The risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.	Approved
Suprofen	Suprofen may decrease the diuretic activities of Torasemide.	Approved, Withdrawn
Tadalafil	Tadalafil may increase the antihypertensive activities of Torasemide.	Approved, Investigational
Tamoxifen	The metabolism of Torasemide can be decreased when combined with Tamoxifen.	Approved
Tamsulosin	The risk or severity of adverse effects can be increased when Torasemide is combined with Tamsulosin.	Approved, Investigational
Tapentadol	The risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Torasemide is combined with Telmisartan.	Approved, Investigational
Temocapril	Torasemide may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Tenoxicam	Tenoxicam may decrease the diuretic activities of Torasemide.	Approved
Terazosin	The risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.	Approved
Terbutaline	Terbutaline may increase the hypokalemic activities of Torasemide.	Approved
Teriflunomide	Teriflunomide may decrease the diuretic activities of Torasemide.	Approved
Terlipressin	Torasemide may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Torasemide is combined with Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	Thiamylal may increase the hypotensive activities of Torasemide.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Torasemide.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Torasemide is combined with Thioridazine.	Withdrawn
Tiaprofenic acid	Tiaprofenic acid may decrease the diuretic activities of Torasemide.	Approved
Tibolone	Torasemide may increase the hypotensive activities of Tibolone.	Approved
Ticagrelor	The metabolism of Torasemide can be decreased when combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Torasemide can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	Torasemide may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Torasemide is combined with Timolol.	Approved
Tinoridine	Tinoridine may decrease the diuretic activities of Torasemide.	Investigational
Tixocortol	Tixocortol may increase the hypokalemic activities of Torasemide.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Torasemide is combined with Tizanidine.	Approved
Tobramycin	The risk or severity of adverse effects can be increased when Torasemide is combined with Tobramycin.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Torasemide.	Approved
Tolazoline	Torasemide may increase the hypotensive activities of Tolazoline.	Approved, Vet Approved
Tolbutamide	The metabolism of Torasemide can be decreased when combined with Tolbutamide.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Torasemide is combined with Tolcapone.	Approved, Withdrawn
Tolfenamic Acid	Tolfenamic Acid may decrease the diuretic activities of Torasemide.	Approved
Tolmetin	Tolmetin may decrease the diuretic activities of Torasemide.	Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Torasemide.	Approved
Topiramate	Torasemide may increase the hypokalemic activities of Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Torasemide is combined with Trandolapril.	Approved
Tranilast	Tranilast may decrease the diuretic activities of Torasemide.	Approved, Investigational
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Torasemide.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Torasemide.	Approved
Travoprost	Torasemide may increase the hypotensive activities of Travoprost.	Approved
Treprostinil	Torasemide may increase the hypotensive activities of Treprostinil.	Approved, Investigational
Tretinoin	The risk or severity of adverse effects can be increased when Torasemide is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamcinolone	Triamcinolone may increase the hypokalemic activities of Torasemide.	Approved, Vet Approved
Triamterene	The risk or severity of adverse effects can be increased when Torasemide is combined with Triamterene.	Approved
Trichlormethiazide	Torasemide may increase the hypotensive activities of Trichlormethiazide.	Approved, Vet Approved
Trimazosin	Torasemide may increase the hypotensive activities of Trimazosin.	Experimental
Trimethaphan	Torasemide may increase the hypotensive activities of Trimethaphan.	Approved
Trimethoprim	The metabolism of Torasemide can be decreased when combined with Trimethoprim.	Approved, Vet Approved
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Torasemide.	Withdrawn
Tubocurarine	Torasemide may decrease the neuromuscular blocking activities of Tubocurarine.	Approved
Udenafil	Udenafil may increase the antihypertensive activities of Torasemide.	Approved, Investigational
Unoprostone	Torasemide may increase the hypotensive activities of Unoprostone.	Approved
Valdecoxib	Valdecoxib may decrease the diuretic activities of Torasemide.	Investigational, Withdrawn
Valproic Acid	The metabolism of Torasemide can be decreased when combined with Valproic Acid.	Approved, Investigational
Valrubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Valrubicin.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Torasemide.	Approved
Vecuronium	Torasemide may decrease the neuromuscular blocking activities of Vecuronium.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Torasemide is combined with Verapamil.	Approved
Vilanterol	Vilanterol may increase the hypokalemic activities of Torasemide.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide.	Approved, Investigational
Vinpocetine	Torasemide may increase the hypotensive activities of Vinpocetine.	Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Torasemide.	Approved, Investigational
Voriconazole	The metabolism of Torasemide can be decreased when combined with Voriconazole.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be increased when it is combined with Torasemide.	Approved
Xylometazoline	Torasemide may increase the hypotensive activities of Xylometazoline.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Torasemide.	Approved, Vet Approved
Zafirlukast	The metabolism of Torasemide can be decreased when combined with Zafirlukast.	Approved, Investigational
Zaltoprofen	Zaltoprofen may decrease the diuretic activities of Torasemide.	Approved
Zileuton	Zileuton may decrease the diuretic activities of Torasemide.	Approved, Investigational, Withdrawn
Zomepirac	Zomepirac may decrease the diuretic activities of Torasemide.	Withdrawn
Zorubicin	The risk or severity of adverse effects can be increased when Torasemide is combined with Zorubicin.	Experimental

Food Interactions

Not Available

References

Synthesis Reference

Fritz Topfmeier, Gustav Lettenbauer, "Process for the preparation of a stable modification of torasemide." U.S. Patent USRE0345806, issued June, 1975.

USRE0345806

General References

Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212 ]
Authors unspecified: FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. [PubMed:8197389 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14359
KEGG Drug	D00382
PubChem Compound	41781
PubChem Substance	46504760
ChemSpider	38123
BindingDB	64107
ChEBI	9637
ChEMBL	CHEMBL1148
Therapeutic Targets Database	DAP000745
PharmGKB	PA451733
Drug Product Database	286
RxList	http://www.rxlist.com/cgi/generic/demadex.htm
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/dem1634.shtml
Wikipedia	Torasemide

ATC Codes

C03CA04 — Torasemide

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (110 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Not Available	To Determine Bioequivalence Under Fasting Conditions	1
1	Completed	Basic Science	Drug Biotransformation / Membrane Transport	1
1	Completed	Basic Science	Genotype-related Drug Metabolism	1
1	Completed	Treatment	Type 2 Diabetes Mellitus	1
1	Terminated	Treatment	Heart Failure, Unspecified / Impaired Renal Function	1
2	Recruiting	Prevention	PreEclampsia	1
2, 3	Completed	Treatment	Heart Failure, Unspecified	1
4	Completed	Treatment	Hypertensive	2
4	Completed	Treatment	Right Heart Failure / Tricuspid valve incompetence	1
4	Recruiting	Treatment	Heart Failure, Unspecified	1
4	Unknown Status	Treatment	Arterial Hypertension / Chronic Heart Failure (CHF)	1
Not Available	Completed	Treatment	Edema	2
Not Available	Not Yet Recruiting	Treatment	Heart Failure, Unspecified	1
Not Available	Terminated	Diagnostic	Acute Decompensated Heart Failure (ADHF)	1

Pharmacoeconomics

Manufacturers

Hoffmann la roche inc
Bedford laboratories
Luitpold pharmaceuticals inc
Meda pharmaceuticals inc
Apotex inc etobicoke site
Aurobindo pharma ltd
Hetero drugs ltd
Par pharmaceutical inc
Pliva pharmaceutical industry inc
Roxane laboratories inc
Sun pharmaceutical industries ltd
Teva pharmaceuticals usa inc

Packagers

American Regent
Apotex Inc.
Aurobindo Pharma Ltd.
Camber Pharmaceuticals Inc.
Cardinal Health
Diversified Healthcare Services Inc.
F Hoffmann-La Roche Ltd.
General Injectables and Vaccines Inc.
Greenstone LLC
Heartland Repack Services LLC
Hetero Drugs Ltd.
Ivax Pharmaceuticals
Mckesson Corp.
Meda AB
Murfreesboro Pharmaceutical Nursing Supply
Neuman Distributors Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
Physicians Total Care Inc.
Pliva Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Resource Optimization and Innovation LLC
Roxane Labs
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral	10 mg/1
Tablet	Oral	100 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	5 mg/1
Liquid	Intravenous	10 mg
Tablet	Oral	100 mg
Tablet	Oral	10 mg
Tablet	Oral	20 mg
Tablet	Oral	5 mg
Injection	Intravenous	10 mg/mL
Injection, solution	Intravenous	10 mg/mL

Prices

Unit description	Cost	Unit
Demadex 100 mg tablet	5.69USD	tablet
Torsemide 100 mg tablet	3.16USD	tablet
Demadex 20 mg tablet	1.59USD	tablet
Demadex 10 mg tablet	1.39USD	tablet
Demadex 5 mg tablet	1.28USD	tablet
Torsemide 20 mg tablet	0.85USD	tablet
Torsemide 10 mg tablet	0.73USD	tablet
Torsemide 5 mg tablet	0.66USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	164-164 °C	Not Available
water solubility	Water soluble	Not Available
logP	2.3	Not Available
pKa	7.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0596 mg/mL	ALOGPS
logP	1.76	ALOGPS
logP	1.86	ChemAxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	5.92	ChemAxon
pKa (Strongest Basic)	4.2	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	100.19 Å²	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	91.89 m³·mol^-1	ChemAxon
Polarizability	36.15 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	+	0.6871
Caco-2 permeable	-	0.5374
P-glycoprotein substrate	Non-substrate	0.799
P-glycoprotein inhibitor I	Non-inhibitor	0.7695
P-glycoprotein inhibitor II	Non-inhibitor	0.8232
Renal organic cation transporter	Non-inhibitor	0.9185
CYP450 2C9 substrate	Substrate	0.6049
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.7558
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.6692
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Inhibitor	0.5905
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6324
Ames test	Non AMES toxic	0.9133
Carcinogenicity	Non-carcinogens	0.8366
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	1.8740 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9854
hERG inhibition (predictor II)	Non-inhibitor	0.8668

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0090000000-bcaf4981571fb662df86	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0090000000-00cc7369c05298ea1c97	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-03di-0490000000-60171fe07a2f255596e3	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-01ot-2950000000-359d6835f9bf703a0701	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-000t-3910000000-a5ec65a6dbedfe7a30d3	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , negative	splash10-0564-6900000000-051171526b146f5d076c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-03di-0091000000-548edfa45514c501788d	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-03di-0090000000-d7326b2b38380cd06e26	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-03di-0490000000-b9f43c4768937947d77f	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-001i-0940000000-7b7084526f7c13bf6443	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-00lr-0910000000-81aa8c9ff5d9a3cd3c10	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-0159-0900000000-87860a9931a8414432cf	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-03di-1590000000-1b7d966c20cec1451f6c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-03di-0490000000-bd8b6af3fe8d0f10e117	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-02ai-2940000000-5beb0e7e25d393903803	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QFT , positive	splash10-03di-0390000000-314819093d7d5a1f48f4	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Pyridines and derivatives

Direct Parent

Pyridinesulfonamides

Alternative Parents

Toluenes / Sulfonylureas / Dihydropyridines / Secondary ketimines / Organosulfonic acids and derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds

Substituents

Pyridine-3-sulfonamide / Dihydropyridine / Toluene / Sulfonylurea / Monocyclic benzene moiety / Hydropyridine / Benzenoid / Secondary ketimine / Heteroaromatic compound / Organic sulfonic acid or derivatives

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

secondary amino compound, aminopyridine, N-sulfonylurea (CHEBI:9637 )

Targets

Details

1. Solute carrier family 12 member 1

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Sodium:potassium:chloride symporter activity
Specific Function:: Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:: SLC12A1
Uniprot ID:: Q13621
Molecular Weight:: 121449.13 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. [PubMed:17460608 ]
Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. [PubMed:10406837 ]

Enzymes

Details

1. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:: CYP2C8
Uniprot ID:: P10632
Molecular Weight:: 55824.275 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

2. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:: CYP2C9
Uniprot ID:: P11712
Molecular Weight:: 55627.365 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

3. Prostaglandin G/H synthase 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Prostaglandin-endoperoxide synthase activity
Specific Function:: Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:: PTGS1
Uniprot ID:: P23219
Molecular Weight:: 68685.82 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]

Details

4. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Molecular Weight:: 55930.545 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:46

Get DrugBank to go!

Structure for DB00214 (Torasemide)

Targets

References

Enzymes

References

References

References

References